Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

Group 1 - Crinetics Pharma is developing Paltusotine for acromegaly and has positive data from a phase 3 trial [1] - The PDUFA date for Paltusotine is set for September 25, indicating a potential regulatory decision soon [1]